UK Markets closed
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • FTSE 250

    22,336.10
    +266.80 (+1.21%)
     
  • AIM

    1,236.38
    +11.54 (+0.94%)
     
  • GBP/EUR

    1.1609
    -0.0018 (-0.15%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.3582%)
     
  • BTC-GBP

    32,518.51
    -1,231.34 (-3.65%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • DOW

    34,382.13
    +360.73 (+1.06%)
     
  • CRUDE OIL

    65.51
    +0.14 (+0.21%)
     
  • GOLD FUTURES

    1,844.00
    +5.90 (+0.32%)
     
  • NIKKEI 225

    28,084.47
    +636.47 (+2.32%)
     
  • HANG SENG

    28,027.57
    +308.87 (+1.11%)
     
  • DAX

    15,416.64
    +216.94 (+1.43%)
     
  • CAC 40

    6,385.14
    +96.81 (+1.54%)
     

Union Medical Healthcare introduces Dr. Cheng Chi Kong and Aspex Management as strategic shareholders to promote development of medical real estate business in mainland China and Hong Kong

·6-min read


EQS-News / 19/04/2021 / 09:37 UTC+8

[FOR IMMEDIATE RELEASE]

 

 

Union Medical Healthcare introduces Dr. Cheng Chi Kong and Aspex Management as strategic shareholders to promote development of medical real estate business in mainland China and Hong Kong

 

(19 April 2021, Hong Kong) Union Medical Healthcare Limited ("Union Medical Healthcare" or the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group introduces Dr. Cheng Chi Kong, Executive Vice Chairman and Chief Executive Officer of New World Development Co., Ltd. (SEHK stock code: 17), and Aspex Management as its strategic shareholders through shares placement. The move is aimed at promoting the Group's development of medical real estate business in mainland China and Hong Kong.

 

A maximum of 29,636,000 shares of Union Medical Healthcare will be placed at a price of HK$7.80 each, which represents a premium of approximately 2.34% to the average closing price of HK$7.62 per share for the five consecutive trading days immediately before the date of the placing agreement. Such shares will account for approximately 2.77% of the Company's existing issued share capital and approximately 2.69% of its enlarged issued share capital immediately following the placement of the shares. The Group expects to receive net proceeds of approximately HK$231.0 million from the transaction and intends to use them for the expansion of clinic network in Hong Kong and the Greater Bay Area in the People's Republic of China and consolidate the medical and healthcare market through mergers and acquisitions to accelerate the Group's business development in Hong Kong and mainland China. Haitong International Securities Company Limited is the placing agent.

 

This transaction is a private investment by Dr. Cheng Chi Kong. Dr. Cheng is engaged in retail, hotels, and office buildings businesses in Greater China. He founded the K11 brand which combines the concepts of museum and retail. Dr. Cheng also manages commercial and residential properties in core cities of mainland China and leads the development of Victoria Dockside, a large-scale commercial real estate project in Hong Kong, and the Sky City project in Hong Kong International Airport related to medical tourism of New World Development Co., Ltd. The introduction of Dr. Cheng as strategic shareholder will further empower the Group to deploy the medical real estate strategy. Leveraging Dr. Cheng's related strategic value of high-quality investment properties, this will facilitate the Group's precise layout in its business development across Hong Kong and mainland China and deepen the cross-sector cooperation in medical services and residential commercial real estate sectors. In addition, since Dr. Cheng is the executive director of Chow Tai Fook Jewellery Group Co., Ltd. (SEHK stock code: 1929), the strategic collaboration will also empower both parties to fully utilize the respective retail resources and maximize the synergy between healthcare and retail businesses.

Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of Union Medical Healthcare said, "The Group is honored to introduce Dr. Cheng Chi Kong and Aspex Management as its shareholder. Dr. Cheng has extensive experience in the real estate and retail industries while Aspex has an excellent track record in investment. This will strengthen the Group's shareholder base and increase its public float. Union Medical Healthcare has been committed to expanding its business in the Guangdong-Hong Kong-Macao Greater Bay Area since its listing. With the Group's digital technology platform, professional medical team, clinic network and outstanding medical tourism service capability, the Group has laid a solid foundation for its business in the Greater Bay Area. The Group is optimistic about its business development despite the pandemic. During the second half of the financial year ended 31 March 2021, the Group achieved excellent performance in overall sales volume which increased by over 35% year on year, while sales volume of medical services increased by over 100% year on year. The Group expects to establish long-term partnerships with the two investors, press ahead with its strategy for developing the medical real estate business and accelerate the deployment of its resources for business development with precision in the Greater Bay Area as it aims to scale new heights."

 

- End -

 

About Union Medical Healthcare Limited 

Union Medical Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.

 

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories and a professional hair care center HAIR FOREST.

 

*According to an independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

 

About Dr. Cheng Chi Kong

Dr. Cheng Chi Kong, Adrian is a visionary leader and a cultural entrepreneur in a new era. He heads the New World Group and Chow Tai Fook Jewellery Group, and is the founder of the K11 brand and C Ventures. Dr. Cheng is responsible for formulating the strategy for the development strategy and the guiding principle for the operation of the Cheng family's business empire and is the third-generation leader of the Cheng family, which is one of the world's most prominent and influential families. The Cheng family is ranked third in Forbes' "Hong Kong's Richest 2021 List with total assets of over US$88 billion as of 31 December 2020. Dr. Cheng is also a prominent and renowned investor with extensive experience and a strong track record.

 

About Aspex

Aspex Management is an investment management firm focused on pan-Asian opportunities across both the public and private equity markets. The firm looks to invest in industries and partner with companies exposed to large addressable markets with long-term growth potential as well as those undergoing structural changes. Aspex invests capital on behalf of endowments, non-profit foundations, family offices and outsourced investment offices across the globe.

 

For further information, please contact: 

iPR Ogilvy Limited 

Callis Lau / Shana Li / Ada Chew 

Tel: (852) 2136 6952 / 3920 7649 / 3920 7650 

Fax: (852) 3170 6606 

Email: umh@iprogilvy.com 



File: Union Medical Healthcare introduces Dr. Cheng Chi Kong and Aspex Management as strategic shareholders to promote development of medical real estate business in mainland China and Hong Kong

19/04/2021 Dissemination of a Financial Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

show this
show this